ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B
Phase 2
Terminated
- Conditions
- Chronic Hepatitis B
- First Posted Date
- 2002-06-25
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT00040144
- Locations
- 🇨🇳
Clinical Trial Site, Hong Kong, China
Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.
Not Applicable
Terminated
- Conditions
- Chronic Hepatitis B
- First Posted Date
- 2002-05-20
- Last Posted Date
- 2009-08-19
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT00037622
Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection
Phase 2
Completed
- Conditions
- Hepatitis B, Chronic
- First Posted Date
- 2002-04-29
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 79
- Registration Number
- NCT00034359
- Locations
Clinical Trial Site, Novi Sad, Former Yugoslavia
© Copyright 2025. All Rights Reserved by MedPath